Clinical Trials@2x
  • News

    Most Read

    • Seelos Therapeutics begins dosing in study of SLS-002
    • Dr Reddy’s receives DCGI approval for trial of Sputnik V vaccine in India
    • Cyxone screens first patient in Phase II Covid-19 trial

    Most Recent

    Clinical Trials

    Genkyotex’s setanaxib shows favourable safety profile in Phase I trial

    19 Jan 2021
  • Analysis

    Sections

    • Features
    • Comment
    • Projects

    Most Read

    • Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy
    • Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market
    • Novo Nordisk’s makes strides into Alzheimer’s with anti-diabetic drug

    Most Recent

    Clinical Trials

    Biogen’s Spinraza set to increase its chances to maintain a strong position in spinal muscular atrophy

    12 Jan 2021
  • Sectors

    Sections

    • Clinical Trials
    • Approvals
    • Clinical Research
    • Operations
    • Outsourcing
    • Supply Chain
    • Cold Chain
    • Data Management
    • Medical Devices

    Most Read

    • International update: Global Covid infections pass 95.6 million – WHO slams vaccine profiteers
    • How Biden’s $1.9t stimulus package will help tackle Covid
    • REMD-377 topline results highlight the benefits of adjunct therapies in type 1 diabetes

    Most Recent

    International update: Global Covid infections pass 95.6 million – WHO slams vaccine profiteers

    19 Jan 2021
  • Themes
  • Deals

    Most Read

    • Investment firm GI Partners closes Clinical Ink acquisition
    • Investment firm GI Partners to acquire minority interest in Clinical Ink
    • IVI and SNU partner to trial Inovio’s Covid-19 vaccine in Korea

    Most Recent

    Clinical Trials

    Investment firm GI Partners closes Clinical Ink acquisition

    27 Aug 2020
  • Companies

    Sections

    • Company A-Z
    • Company Categories
    • Products & Services
    • Company Releases
    • White Papers
    • Videos

    Most Read

    • Linari NanoTech
    • OpenClinica
    • Strategikon Pharma

    Most Recent

    Linari NanoTech

    19 Jan 2021
  • Magazine
  • Events
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Clinical Trials
    • Approvals
    • Clinical Research
    • Operations
    • Outsourcing
    • Supply Chain
    • Cold Chain
    • Data Management
    • Medical Devices
  • Deals
  • Tech
  • Disruption
  • Coronavirus
Partners
  • Accelerating Clinical Trials
  • Simplifying Clinical Trials
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register
Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus

Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus

In this issue: Knock on effects of the Valsartan recall, the future of AI in...

31st January 2019

Latest News

Clinical Trials

Genkyotex’s setanaxib shows favourable safety profile in Phase I trial

19 Jan 2021
Clinical Trials

Debiopharm begins Phase II trial of alisporivir against Covid-19 in France

19 Jan 2021
Clinical Trials

Grifols to initiate new Covid-19 drug trial in Spain

19 Jan 2021
Clinical Trials

Seelos Therapeutics begins dosing in study of SLS-002

18 Jan 2021

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
Clinical Trials

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms and Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more